Compare HIW & IDYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HIW | IDYA |
|---|---|---|
| Founded | 1978 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 1995 | 2019 |
| Metric | HIW | IDYA |
|---|---|---|
| Price | $27.98 | $28.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 16 |
| Target Price | $27.57 | ★ $52.86 |
| AVG Volume (30 Days) | ★ 1.3M | 689.0K |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | ★ 8.43% | N/A |
| EPS Growth | 54.26 | ★ 61.90 |
| EPS | ★ 0.29 | N/A |
| Revenue | ★ $806,112,000.00 | $218,710,000.00 |
| Revenue This Year | $6.03 | N/A |
| Revenue Next Year | $3.58 | $201.05 |
| P/E Ratio | $95.17 | ★ N/A |
| Revenue Growth | N/A | ★ 3024.43 |
| 52 Week Low | $20.45 | $20.50 |
| 52 Week High | $32.76 | $39.28 |
| Indicator | HIW | IDYA |
|---|---|---|
| Relative Strength Index (RSI) | 76.23 | 44.26 |
| Support Level | $25.13 | $27.66 |
| Resistance Level | $27.98 | $29.74 |
| Average True Range (ATR) | 0.66 | 1.02 |
| MACD | 0.11 | 0.06 |
| Stochastic Oscillator | 97.98 | 32.46 |
Highwoods Properties Inc is a fully integrated office REIT that owns, develops, acquires, leases, and manages office properties mainly in the best business districts of Atlanta, Charlotte, Dallas, Nashville, Orlando, Raleigh, Richmond, and Tampa. Its principal business is the operation, acquisition, and development of rental office properties, with no material inter-segment transactions. The Company evaluates performance by geographic location, and the operating results by geographic grouping are regularly reviewed by the chief operating decision maker. The core portfolio consists mainly of office properties in its key markets, with the majority of revenue derived from its Raleigh properties.
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.